Physician profile
Shrinath Barathan
NPI 1710912068
$18,045.02
in general payments reported to CMS, 2019-2025
48 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $1,803 · 2021: $6,263 · 2022: $1,569 · 2023: $1,841 · 2024: $2,544 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,091 · Education: $4.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,090.82 |
| Education | $4.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,184.08 | 2019-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $2,011.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,651.41 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Daiichi Sankyo INC. | $1,184.37 | 2019-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $798.41 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.89 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $601.65 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $570.53 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $516.03 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $510.11 | 2020-2025 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $419.00 | 2021-2025 | |
| Lilly USA, LLC | $357.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Akebia Therapeutics INC | $332.47 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $278.44 | 2019-2025 | Rayaldee |
| Alnylam Pharmaceuticals INC. | $277.03 | 2019-2025 | Oxlumo, Amvuttra |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrinath Barathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.